Triptoreline

Phase 3Small molecule

UUniversitaire Ziekenhuizen KU Leuven

Triptoreline is one of 37 small molecule programs targeting Age. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AgeRecruiting

AgePhase 3

Recruiting

Competition

Competitive Landscape

48 competitors in Age

#DrugCompanyPhaseTrials

Actigall

AbbVie

Approved

—2

Rapamune

PPrism Pharmaceuticals

Venclexta

3 4

Acotiamide

GGetz Pharma

Phase 3

1 5

APG-115

Ascentage Pharma Group Inc.

Phase 2

1 6

APG-2575

Ascentage Pharma Group Inc.

Phase 2

1 7

Funduscein-25

FFalcon

Phase 2

1 8

Imbruvica

PPharmacyclics LLC.

Phase 1

1 9

Triptoreline

UUniversitaire Ziekenhuizen KU Leuven

Phase 3

1 10

Opalustre

CCairo University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 2/3Recruiting

Age

NCT04242017

Clinical

Trials by Indication[1]

Age1 trial

Long-term Better Than Short-term ADT With Salvage RT

Recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 2/3·NCT04242017·394 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Triptoreline. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Triptoreline compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Triptoreline. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universitaire Ziekenhuizen KU Leuven company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversitaire Ziekenhuizen KU Leuven

Triptoreline

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Age1 trial

References

Drug Info

Quick Facts

Related News